Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Update

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) saw a significant decline in short interest in August. As of August 31st, there was short interest totaling 5,707 shares, a decline of 54.4% from the August 15th total of 12,512 shares. Approximately 0.3% of the shares of the stock are short sold. Based on an average trading volume of 16,436 shares, the short-interest ratio is currently 0.3 days.

Alaunos Therapeutics Stock Down 8.2%

NASDAQ:TCRT traded down $0.12 during trading hours on Wednesday, hitting $1.29. 33,705 shares of the company’s stock traded hands, compared to its average volume of 16,450. Alaunos Therapeutics has a 52 week low of $1.32 and a 52 week high of $4.59. The business’s fifty day simple moving average is $1.85 and its two-hundred day simple moving average is $2.41. The firm has a market cap of $3.29 million, a P/E ratio of -0.68 and a beta of -0.97.

Alaunos Therapeutics (NASDAQ:TCRT) last announced its earnings results on Friday, August 14th. The company reported ($0.41) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Alaunos Therapeutics has a consensus rating of “Sell”.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.